Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose escalation study of AMN107 (nilotinib) in combination with imatinib in imatinib-resistant GIST
2005-000561-18Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoints: Maximum tolerated dose of AMN107 in combination with imatinib and Safety and tolerability of AMN107 + imatinib. Started Oct 2005; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2005-000561-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000561-18.